From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Latest Views & News

Fusion Antibodies – CEO has now left after little more than a year… and who’s the successor then?

By Steve Moore | Monday 14 March 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


On 21st February Fusion Antibodies (FAB) announced the resignation of CEO Richard Jones, though stating “Richard will remain with the company while arrangements are put in place for his successor. The board has initiated a formal search for a new CEO”. It has today announced that “Richard Jones has now stepped down from his role as CEO, effective from 11 March 2022”. Who’s the successor then?…

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



That Was the Week that Was

 

ICON

Iconic Labs – its alive!

Wednesday »

Bearcast

Tom Winnifrith Bearcast: Family tales

 

SHG

Shanta Gold – a recovery BUY!

 

MUSH

Oscillate RTO – madness

 

MOON

Surely Moonpig is a short at 171p?

 

Atomic

Video: The Road to an Energy Crisis

 

Bear

Beyond Meat is Beyond Redemption.

Friday »

Bearcast

Tom Winnifrith bearcast: Madness!

 

RRR

The Andrew Bell defence at Red Rock